A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Treatment Resistant Depressive Disorder

Interventions

DRUG: Esketamine 14 mg
DRUG: Esketamine 28 mg
DRUG: Esketamine 56 mg
DRUG: Esketamine 84 mg
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC